Update
$G1 Therapeutics (GTHX.US)$ Meaningful Improvement in Overall Survival (Os) and Tolerability Observed in Patients Receiving Trilaciclib in Combination With a Trop2 Antibody-Drug Conjugate (ADC)! Results Indicate Use of Trilaciclib With Trop2 ADC May Be Associated With Improved Median Os Compared to Historical Data for ADC Alone! On-Target Effect of Trilaciclib Cuts Rates of Multiple Many Adverse Events Associated With Trop2 ADC
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
